Subscribe
Interview with the Innovators

Loretta Fala

Medical Writer

Authored Articles

Truseltiq (Infigratinib) New Targeted Therapy FDA Approved for Advanced or Metastatic Cholangiocarcinoma Harboring FGFR2 Alterations
Loretta Fala
Cholangiocarcinoma, Drug Updates
August 2021, Vol 12, No 4
Read Article
Pemazyre (Pemigatinib) First Targeted Therapy FDA Approved for Cholangiocarcinoma with FGFR2 Biomarker
Loretta Fala
Cholangiocarcinoma
June 2020, Vol 11, No 3
Read Article
Yescarta (Axicabtagene Ciloleucel) Second CAR T-Cell Therapy Approved for Patients with Certain Types of Large B-Cell Lymphoma
Loretta Fala
FDA Approvals, News & Updates, Hematologic Malignancies, Lymphoma
2018 Third Annual Oncology Guide to New FDA Approvals
Read Article
Verzenio (Abemaciclib) a New CDK4/CDK6 Inhibitor Approved for HR-Positive, HER2-Negative Advanced or Metastatic Breast Cancer
Loretta Fala
Breast Cancer, FDA Approvals, News & Updates, Solid Tumors
2018 Third Annual Oncology Guide to New FDA Approvals
Read Article
Kymriah (Tisagenlecleucel) for Young Patients with Acute Lymphoblastic Leukemia: First FDA-Approved Gene Therapy
Loretta Fala
FDA Approvals, News & Updates, Leukemia
2018 Third Annual Oncology Guide to New FDA Approvals
Read Article
Akynzeo (Netupitant and Palonosetron), a Dual-Acting Oral Agent, Approved by the FDA for the Prevention of Chemotherapy-Induced Nausea and Vomiting
Loretta Fala
Drug Updates
May 2015, Vol 6, No 4
Read Article
Lenvima (Lenvatinib), a Multireceptor Tyrosine Kinase Inhibitor, Approved by the FDA for the Treatment of Patients with Differentiated Thyroid Cancer
Loretta Fala
Drug Updates
April 2015, Vol 6, No 3
Read Article
Cyramza (Ramucirumab) Approved for the Treatment of Advanced Gastric Cancer and Metastatic Non–Small-Cell Lung Cancer
Loretta Fala
Drug Updates
March 2015, Vol 6, No 2
Read Article
Tafinlar (Dabrafenib)/Mekinist (Trametinib) Combination Therapy Received Accelerated FDA Approval for the Treatment of Patients with Metastatic Melanoma
Loretta Fala
Drug Updates
June 2014, Vol 5, No 5
Read Article

Stay In The Know

Stay up to date on the matters of value in cancer by signing up for the free, bi-monthly VBCC print publication and VBCC weekly e‑newsletter.

Subscribe
© Amplity Health. All Rights Reserved. Privacy Policy.